Viskupič Filip, Wiltse David L
Department of Political Science, Iowa State University of Science and Technology, Ames, Iowa, United States of America.
School of American and Global Studies, South Dakota State University, Brookings, South Dakota, United States of America.
PLOS Glob Public Health. 2025 Sep 10;5(9):e0005180. doi: 10.1371/journal.pgph.0005180. eCollection 2025.
It is possible that the negative attitudes toward COVID-19 vaccination developed by some people, such as self-identified Republicans, might spill over toward other vaccines. We conducted a survey experiment to investigate if mentioning COVID-19 vaccine in messages encouraging seasonal flu vaccination will negatively affect people's attitudes toward receiving a flu vaccine. The experiment was embedded in a survey fielded in South Dakota in April 2024. Participants were registered voters in the state. We used difference-of-means tests and logistic regression to analyze the data. Results showed no statistically significant differences between the participants in control and treatment groups regarding the likelihood of receiving a flu vaccine (OR: 1.012, CI: 0.594 - 1.724) or their belief in the safety of the flu vaccine (OR: 1.333, CI: 0.707- 2.511). We observed the same patterns when we only looked at Republicans. Attitudes toward flu vaccination were primarily driven by peoples' current flu vaccination status. We found that mentioning COVID-19 vaccines in flu vaccination messages did not negatively affect people's attitudes toward flu vaccine. Public health workers and officials might not need to shy away from mentioning COVID-19 vaccines when communicating other vaccines.
一些人,比如自称共和党人的那些人,对新冠疫苗接种持有的负面态度,有可能会蔓延到其他疫苗上。我们进行了一项调查实验,以探究在鼓励季节性流感疫苗接种的信息中提及新冠疫苗是否会对人们接受流感疫苗的态度产生负面影响。该实验嵌入在2024年4月在南达科他州进行的一项调查中。参与者是该州的登记选民。我们使用均值差异检验和逻辑回归来分析数据。结果显示,在接受流感疫苗的可能性(比值比:1.012,置信区间:0.594 - 1.724)或对流感疫苗安全性的信念方面,对照组和治疗组的参与者之间没有统计学上的显著差异(比值比:1.333,置信区间:0.707 - 2.511)。当我们只看共和党人时,观察到了相同的模式。对流感疫苗接种的态度主要由人们当前的流感疫苗接种状况驱动。我们发现,在流感疫苗接种信息中提及新冠疫苗不会对人们对流感疫苗的态度产生负面影响。公共卫生工作者和官员在宣传其他疫苗时,可能无需回避提及新冠疫苗。